Core Viewpoint - Wenzhi Traditional Chinese Medicine has submitted its listing application to the Hong Kong Stock Exchange, with Haitong International as its sole sponsor [1] Group 1: Market Position - Wenzhi Traditional Chinese Medicine is projected to be the largest AI-assisted traditional Chinese medicine service provider in mainland China in 2023 and 2024, with market shares of 1.5% and 1.3% respectively [1] Group 2: Product and Service Offerings - The company has developed "Traditional Chinese Medicine Brain," which is the first and only AI-assisted diagnostic system for traditional Chinese medicine in mainland China, validated through clinical consistency studies and expert reviews from top-tier hospitals [1] - Wenzhi generates revenue through traditional Chinese medicine services, wellness and knowledge products, and subscription services for the TCM Brain [1] Group 3: Community Engagement - The establishment of "Jingyi Academy" has resulted in the largest registered TCM community in mainland China, promoting TCM culture and knowledge sharing, while also accumulating potential customers for the company's business [1]

Core Viewpoint - The company, Wenzhi Traditional Chinese Medicine, has submitted a listing application to the Hong Kong Stock Exchange, with Haitong International as the sole sponsor. This follows a previous application made on January 9, 2025 [1]. Company Overview - Wenzhi Traditional Chinese Medicine is recognized as the largest provider of AI-assisted traditional Chinese medicine (TCM) medical services in mainland China for 2023 and 2024, holding market shares of 1.5% and 1.3% respectively. AI-assisted TCM services utilize AI technology to support clinical decision-making based on the expertise of senior TCM practitioners [3]. - The company has established a comprehensive TCM business model that addresses customer needs from disease treatment to health maintenance and TCM education [3]. Financial Performance - The revenue figures for Wenzhi Traditional Chinese Medicine are as follows: - 2022: 62.169 million RMB - 2023: approximately 188.998 million RMB - 2024: approximately 236.414 million RMB - Five months ending May 31, 2024: 89.848 million RMB - Five months ending May 31, 2025: approximately 100.392 million RMB - The company reported losses of approximately 154.421 million RMB in 2022, 193.914 million RMB in 2023, and 45.367 million RMB in 2024 [5][6]. Market Characteristics - The TCM medical services industry in mainland China is highly fragmented, with significant potential for development and integration. However, there are challenges on both the supply and demand sides. The supply side is particularly constrained by a shortage of skilled and experienced TCM practitioners, with only about 760,000 licensed TCM practitioners in 2024, of which less than 5% are senior practitioners [4].